Literature DB >> 15509615

Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients.

Michael Hogardt1, Sabine Schmoldt, Monika Götzfried, Kristin Adler, Jürgen Heesemann.   

Abstract

OBJECTIVES AND METHODS: With their potent activity against Gram-negative bacteria, the polymyxins are important alternative antibiotics for cystic fibrosis (CF) patients. A retrospective evaluation of polymyxin activity against 6001 Pseudomonas aeruginosa, 150 Achromobacter xylosoxidans and 506 Stenotrophomonas maltophilia CF isolates was initiated. In addition, we looked at how polymyxin susceptibility testing was affected by the testing method (agar dilution versus microdilution), the agent (polymyxin E versus polymyxin B), incubation time (24 h versus 48 h) and by different interpretative criteria (German DIN, French FSM, British BSAC).
RESULTS: Polymyxin B exhibited reasonable activity against P. aeruginosa (MIC(90)< or =2 mg/L), whereas it was less active against A. xylosoxidans (MIC(90)< or =16 mg/L) and S. maltophilia (MIC(90)< or =16 mg/L). During 2000-2002, polymyxin B resistance in P. aeruginosa, S. maltophilia and A. xylosoxidans was found to be 6.7%, 17.0% and 29.9% (corresponding to 12.4%, 20.7% and 35.4% of infected patients), respectively. When the agar dilution method was used, polymyxin E exhibited higher MICs than polymyxin B. The microdilution method produced lower polymyxin MICs than the agar dilution method. Therefore, the microdilution MICs after prolonged incubation (48 h) and the agar dilution MICs of polymyxin B correlated best (AUC of 0.93, r(2) of 0.44 and s of 0.83).
CONCLUSIONS: Polymyxin resistance among common CF pathogens is not rare, thus underlining the necessity of accurate susceptibility testing. When compared with the agar dilution method, it was found that the microdilution method is a valid, rapid and cost effective alternative for the determination of polymyxin activity. The performance of the microdilution method was most reliable after prolonged incubation (48 h) at a susceptibility breakpoint of < or =4 mg/L according to the BSAC guidelines (specificity 91%, sensitivity 89%, 1.5% very major errors).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15509615     DOI: 10.1093/jac/dkh470

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  21 in total

Review 1.  The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.

Authors:  Matthew E Falagas; Sofia K Kasiakou; Sotirios Tsiodras; Argyris Michalopoulos
Journal:  Clin Med Res       Date:  2006-06

2.  Increased susceptibility to colistin in hypermutable Pseudomonas aeruginosa strains from chronic respiratory infections.

Authors:  M D Maciá; A Mena; N Borrell; J L Pérez; A Oliver
Journal:  Antimicrob Agents Chemother       Date:  2007-09-24       Impact factor: 5.191

Review 3.  Polymyxins revisited.

Authors:  David Landman; Claudiu Georgescu; Don Antonio Martin; John Quale
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

4.  Colistin: the phoenix arises.

Authors:  Jm Conly; Bl Johnston
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

Review 5.  Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations.

Authors:  Fereshteh Ezadi; Abdollah Ardebili; Reza Mirnejad
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

Review 6.  Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.

Authors:  Laurent Poirel; Aurélie Jayol; Patrice Nordmann
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

Review 7.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

8.  Evaluation of colistin susceptibility in multidrug-resistant clinical isolates from cystic fibrosis, France.

Authors:  S Biswas; J-C Dubus; M Reynaud-Gaubert; N Stremler; J-M Rolain
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-05-30       Impact factor: 3.267

9.  Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli.

Authors:  Janet A Hindler; Romney M Humphries
Journal:  J Clin Microbiol       Date:  2013-03-13       Impact factor: 5.948

10.  Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes.

Authors:  Mark A Toleman; Peter M Bennett; David M C Bennett; Ronald N Jones; Timothy R Walsh
Journal:  Emerg Infect Dis       Date:  2007-04       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.